Integer Holdings Surges As Analysts Lift Price Targets

Integer Holdings Corporation stocks have been trading up by 20.18 percent after strong earnings guidance and robust medical device demand.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ITGR

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Freedom Capital started coverage with a Buy rating and a $112 target, calling Integer Holdings a scaled specialty CDMO and viewing the expected 2026 dip in sales and earnings as temporary in a broader growth path.
Truist raised its target from $97 to $110 and kept a Buy rating, even while pointing to weak demand and low capital spending across medtech.
Citi lifted its target to $96 from $92 with a Neutral stance, seeing Integer Holdings as a higher-quality medtech name that could benefit if traders rotate toward safety.
Street consensus on Integer Holdings is overweight with an average target near $99.44, signaling broadly constructive expectations.
The company has set its Q2 2026 earnings conference call, which will cover recent results, business trends, and other forward-looking comments.

Weekly Update Jul 27 – Jul 31, 2026: On Friday, July 31, 2026 Integer Holdings Corporation stock [NYSE: ITGR] is trending up by 20.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Integer Holdings (ITGR) is a scaled specialty medtech CDMO with solid fundamentals and balanced risk. Revenue of ~$1.85B growing high single to low double digits (3–5 year CAGR) and a 26% gross margin support an 18.8% EBITDA margin, but ROIC in the mid‑single digits and 7–8% net margins indicate underutilized earning power. Leverage is manageable (total debt/equity 0.8x, interest coverage 8.4x; current ratio 3.8x). Free cash flow conversion is weak near term (Q1 FCF only ~$0.7M) due to working‑capital drag and capex, partially offset by disciplined capital returns and M&A flexibility. The stock’s 34x P/E and ~1.8x sales multiple price in continued growth and margin stability versus broader medtech, but tangible book is negative and returns lag best‑in‑class CDMOs, arguing for only a modest valuation premium.

Technically, ITGR is in a clear bullish breakout. The rapid move from the $99–101 area to ~$121 on the latest weekly bar signals a strong upside momentum expansion after consolidating around $100. Volume on the breakout has been elevated on intraday data, confirming institutional participation. Near term, $100–101 is now critical support and should be used as a stop‑loss reference for new positions. Upside trading focus is a continuation toward $125, with tactical add‑zones on pullbacks into the $110–112 area, where prior resistance should convert to support.

More Breaking News

Near‑term catalysts are skewed favorably. Multiple brokers (Freedom Capital, Truist, Citi) have lifted targets into the mid‑90s to low‑110s, with Truist and Freedom explicitly framing 2026 headwinds as transitory within a durable growth story. Integer screens attractively versus the broader Healthcare and Medical Equipment & Supplies space on growth, scale, and CDMO positioning, though its ROIC and FCF profile trail sector leaders. With sentiment inflecting, I see an intermediate‑term fair value range of $120–130, with strong support at $100 and secondary support near $110; near‑term resistance emerges at $125.

Quick Financial Overview

Integer Holdings Corporation (ITGR) is trading in a strong uptrend based on the latest weekly and intraday data. The weekly close jumped from around $100 to about $120.90, a sharp upward repricing that lines up with a cluster of positive analyst moves. Intraday, the stock spent most of the session grinding around $100 before exploding higher above $120 in the afternoon, a classic momentum breakout on a catalyst-driven tape.

On the fundamentals, Integer Holdings generated roughly $1.85B in revenue over the last period, with gross margin near 26.4% and EBITDA margin around 18.8%. Profit margin sits in the mid‑single digits, and the price/earnings multiple near 34.5 suggests traders are already paying up for growth. Price-to-sales at about 1.83 and price-to-book near 1.94 point to a premium, but not extreme, valuation for a specialized medtech manufacturer.

Balance sheet metrics matter for swing traders here. A current ratio of 3.8 and quick ratio of 1.6 show solid liquidity, while total debt-to-equity of 0.81 and interest coverage of 8.4 indicate manageable leverage. Cash flow from operations of about $24.7M in the latest quarter supports the story, even after factoring capex that pulls free cash flow close to flat. Return on equity in the high single digits and asset turnover at 0.6 confirm a steady, though not explosive, efficiency profile.

Conclusion

Integer Holdings Corporation has lined up a powerful mix of price action and supportive analyst coverage that traders cannot ignore. The sudden shift from a tight $100 range into the low $120s, in the same window that Freedom Capital, Truist, and Citi all raised targets, shows how sentiment can flip quickly once the Street leans the same way. When a name with solid margins and steady cash generation starts to break out technically, short‑term traders often step in to ride that move.

At the same time, ITGR is not a cheap turnaround story. A mid‑30s earnings multiple and talk of an anticipated 2026 sales and earnings dip mean the bar is elevated and expectations are sensitive to any hint of slowdown. The upcoming Q2 2026 earnings call, already scheduled by Integer Holdings, will be watched as the next major information release where management can either reinforce or undercut the current bullish tone. For traders, the key is balancing the upside from fresh analyst targets against the risk that guidance may highlight the temporary softness ahead.

From a trading-education standpoint, Integer Holdings Corporation is a clean example of how fundamentals, Street opinion, and chart action align into a focused opportunity. This is exactly the kind of situation where discipline and patience matter, and where a clear trading process can help keep emotions in check. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. As I often tell my students, “The best trades set up when strong price action, improving sentiment, and clear catalysts all point in the same direction — your job is to manage risk, not predict the future.”

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!